TOday’s Movers: BTG PLC (LON:BTG) Stock Rating Has Been Reiterated by Analysts at Jefferies International; GBX 850.00 Target Price Indicates 34.97% Potential

Share

BTG PLC (LON:BTG) Rating Reaffirmed

BTG PLC (LON:BTG) just had their share rating of a ‘”Buy”‘ issued by research analysts at Jefferies International, who now has a GBX 850.00 target on the 2.41 billion GBP market cap company or a 34.97% upside potential. This key information was disclosed to clients in an analyst note on 14 December.

From a total of 6 analysts covering BTG PLC (LON:BTG) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is GBX 1100 while the lowest target price is GBX 550. The mean of all analyst targets is GBX 771 with a 22.48% above today’s (GBX 629.5) stock price. BTG PLC was the topic of 26 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on December 14 with “Buy” rating. Stifel Nicolaus maintained shares with “Sell” rating and GBX 550 target share price in a report from an October 6. Jefferies maintained BTG stock in a recent report from November 12 with “Buy” rating. Finally, Panmure Gordon maintained the stock with “Buy” rating in a report issued on a November 10.

Approximately 132,167 shares of stock traded hands. BTG plc (LON:BTG) has declined 20.28% since May 15, 2015 and is downtrending. It has underperformed by 15.87% the S&P500.

TOday’s Movers: BTG PLC (LON:BTG) Stock Rating Has Been Reiterated by Analysts at Jefferies International; GBX 850.00 Target Price Indicates 34.97% Potential

BTG plc is a specialist healthcare company. The company has a market cap of 2.41 billion GBP. The Firm operates in three business divisions: Interventional Medicine (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). It has 53.72 P/E ratio. The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.

According to Zacks Investment Research, “B2Gold Corp. is involved in the exploration and development of gold. The company’s assets are situated in Nicaragua, Colombia, Namibia and Uruguay. B2Gold Corp. is headquartered in Vancouver, Canada.”

COMMENTS: